Pan-cancer analyses based on the TCGA database, along with multiple independent studies, have demonstrated that ANLN is overexpressed in diverse malignancies, including cancers of the lung, breast, liver(hepatocellular carcinoma), pancreas, and prostate, among others, suggesting its involvement in tumorigenesis and disease progression. The gene discussed is ANLN; the disease is hepatocellular carcinoma.